{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:44:41Z","timestamp":1780551881652,"version":"3.54.1"},"reference-count":56,"publisher":"Georg Thieme Verlag KG","issue":"06","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment of epilepsy has advanced over the past 30 years through the development of new antiseizure medications (ASMs). Unfortunately, not all of them have been approved yet in Brazil, and many are still underused. When comparing new ASMs to older ones, they are generally not more effective in treating epilepsy. However, they offer better tolerability, with fewer interactions and long-term side effects, especially for patients with comorbidities or those requiring polytherapy. Enzyme induction caused by older ASMs is associated with increased cholesterol levels, drug interactions with decreased effects of statins and other cardiovascular medications, anticoagulants, chemotherapy, immunosuppressors, anti-infective agents (including HIV treatment), antidepressants, and contraceptives. Additionally, they can reduce levels of vitamin D and sex hormones, as well as decrease bone density. The increasing concern about these effects during life, especially after prolonged exposure, has led most developed countries to change prescription patterns in favor of new ASMs, particularly levetiracetam and lamotrigine. Both are also considered the safest options for women of childbearing age. Regrettably, the prescription trends in Brazil have remained largely unchanged over time. This can be partially attributed to the slower approval process of ASM and the reluctance of general physicians and neurologists to embrace these new concepts. In this concise review, we highlight the various advantages linked to the new ASM, aiming to promote a shift in the prescription pattern for ASM. The selection of ASM should be customized according to individual characteristics, and practical suggestions for choosing ASMs are provided in this paper.<\/jats:p>","DOI":"10.1055\/s-0043-1777806","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:11:44Z","timestamp":1711498304000},"page":"001-010","source":"Crossref","is-referenced-by-count":5,"title":["Practices in the prescription of antiseizure medications: is it time to change?"],"prefix":"10.1055","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2694-5120","authenticated-orcid":false,"given":"L\u00e9cio Figueira","family":"Pinto","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Hospital das Cl\u00ednicas, Instituto Central, Divis\u00e3o de Cl\u00ednica Neurol\u00f3gica, S\u00e3o Paulo SP, Brazil."},{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Hospital das Cl\u00ednicas, Instituto de Psiquiatria, Programa de Neuropsiquiatria (PROJEPSI) S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-8456","authenticated-orcid":false,"given":"Lucas Sc\u00e1rdua","family":"Silva","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas SP, Brazil."},{"name":"Universidade Estadual de Campinas, Faculdade de Ci\u00eancias M\u00e9dicas, Departamento de Neurologia, Campinas SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4518-2090","authenticated-orcid":false,"given":"Rafael Batista","family":"Jo\u00e3o","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas SP, Brazil."},{"name":"Universidade Estadual de Campinas, Faculdade de Ci\u00eancias M\u00e9dicas, Departamento de Neurologia, Campinas SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3984-2689","authenticated-orcid":false,"given":"Vin\u00edcius","family":"Boldrini","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas SP, Brazil."},{"name":"Universidade Estadual de Campinas, Faculdade de Ci\u00eancias M\u00e9dicas, Departamento de Neurologia, Campinas SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9336-9568","authenticated-orcid":false,"given":"Fernando","family":"Cendes","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas SP, Brazil."},{"name":"Universidade Estadual de Campinas, Faculdade de Ci\u00eancias M\u00e9dicas, Departamento de Neurologia, Campinas SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-7173","authenticated-orcid":false,"given":"Clarissa Lin","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas SP, Brazil."},{"name":"Universidade Estadual de Campinas, Faculdade de Ci\u00eancias M\u00e9dicas, Departamento de Neurologia, Campinas SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.yebeh.2014.10.021","article-title":"Cosmetic side effects of antiepileptic drugs in adults with epilepsy","volume":"42","author":"B Chen","year":"2015","journal-title":"Epilepsy Behav"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"B Chen","year":"2017","journal-title":"Epilepsy Behav"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.seizure.2018.09.014","article-title":"Cross-sensitivity of psychiatric and behavioral side effects with antiepileptic drug use","volume":"62","author":"B Chen","year":"2018","journal-title":"Seizure"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1212\/WNL.0b013e31823efcf8","article-title":"Evidence-based guideline: Antiepileptic drug selection for people with HIV\/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy","volume":"78","author":"G L Birbeck","year":"2012","journal-title":"Neurology"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"T Glauser","year":"2013","journal-title":"Epilepsia"},{"issue":"09","key":"ref6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"P Perucca","year":"2012","journal-title":"Lancet Neurol"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","article-title":"30 years of second-generation antiseizure medications: impact and future perspectives","volume":"19","author":"E Perucca","year":"2020","journal-title":"Lancet Neurol"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"G Zaccara","year":"2014","journal-title":"Epileptic Disord"},{"issue":"08","key":"ref9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs: a systematic review of their efficacy and tolerability","volume":"38","author":"A G Marson","year":"1997","journal-title":"Epilepsia"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/WCO.0000000000000803","article-title":"What has been the impact of new drug treatments on epilepsy?","volume":"33","author":"Z Chen","year":"2020","journal-title":"Curr Opin Neurol"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","article-title":"Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma","volume":"52","author":"W L\u00f6scher","year":"2011","journal-title":"Epilepsia"},{"issue":"9566","key":"ref12","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"A G Marson","year":"2007","journal-title":"Lancet"},{"issue":"9566","key":"ref13","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"A G Marson","year":"2007","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.seizure.2020.12.005","article-title":"Alternatives to valproate in girls and women of childbearing potential with Idiopathic Generalized Epilepsies: state of the art and guidance for the clinician proposed by the Epilepsy and Gender Commission of the Italian League Against Epilepsy (LICE)","volume":"85","author":"B Mostacci","year":"2021","journal-title":"Seizure"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0140-6736(21)00435-9","article-title":"Newer versus older antiseizure medications: further forward?","volume":"397","author":"J H Cross","year":"2021","journal-title":"Lancet"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.14581\/jer.14010","article-title":"Old versus New: Why Do We Need New Antiepileptic Drugs?","volume":"4","author":"S K Lee","year":"2014","journal-title":"J Epilepsy Res"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"M J Brodie","year":"2013","journal-title":"Epilepsia"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/epi.14554","article-title":"Impact of carbamazepine, lamotrigine, and levetiracetam on vascular risk markers and lipid-lowering agents in the elderly","volume":"59","author":"S Mintzer","year":"2018","journal-title":"Epilepsia"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1528-1157.2003.44802.x","article-title":"Lipoprotein(a) concentration increases during treatment with carbamazepine","volume":"44","author":"S Br\u00e4mswig","year":"2003","journal-title":"Epilepsia"},{"issue":"07","key":"ref20","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1528-1167.2011.03118.x","article-title":"Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers","volume":"52","author":"J Bullman","year":"2011","journal-title":"Epilepsia"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jamaneurol.2021.3424","article-title":"Association of Enzyme-Inducing Antiseizure Drug Use With Long-term Cardiovascular Disease","volume":"78","author":"C B Josephson","year":"2021","journal-title":"JAMA Neurol"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/epi4.12227","article-title":"Discontinuation of carbamazepine due to concerns of long-term consequences of enzyme induction","volume":"3","author":"J M\u00e4kinen","year":"2018","journal-title":"Epilepsia Open"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2016.05.023","article-title":"Changes in hormone and lipid levels in male patients with focal seizures when switched from carbamazepine to lacosamide as adjunctive treatment to levetiracetam: A small phase IIIb, prospective, multicenter, open-label trial","volume":"62","author":"C E Elger","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ncl.2010.03.026","article-title":"The selection of antiepileptic drugs for the treatment of epilepsy in children and adults","volume":"28","author":"J J Asconap\u00e9","year":"2010","journal-title":"Neurol Clin"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s11940-012-0180-y","article-title":"Seizure treatment in transplant patients","volume":"14","author":"P W Shepard","year":"2012","journal-title":"Curr Treat Options Neurol"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1684\/epd.2019.1105","article-title":"Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy","volume":"21","author":"T Tomson","year":"2019","journal-title":"Epileptic Disord"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ana.26561","article-title":"Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations","volume":"93","author":"J M Cohen","year":"2023","journal-title":"Ann Neurol"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jamaneurol.2020.0032","article-title":"Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy","volume":"77","author":"B AA Alsfouk","year":"2020","journal-title":"JAMA Neurol"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1590\/0004-282x-anp-2020-0012","article-title":"Trends in prescribing patterns of antiepileptic drugs among older adult inpatients in a Brazilian tertiary center","volume":"79","author":"T Assis","year":"2021","journal-title":"Arq Neuropsiquiatr"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1744-8603-8-6","article-title":"Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?","volume":"8","author":"A D Bertoldi","year":"2012","journal-title":"Global Health"},{"issue":"12","key":"ref31","doi-asserted-by":"crossref","first-page":"e032551","DOI":"10.1136\/bmjopen-2019-032551","article-title":"Trends in antiepileptic drug treatment and effectiveness in clinical practice in England from 2003 to 2016: a retrospective cohort study using electronic medical records","volume":"9","author":"G Powell","year":"2019","journal-title":"BMJ Open"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12883-017-0837-y","article-title":"Health care cost associated with the use of enzyme-inducing and non-enzyme-active antiepileptic drugs in the UK: a long-term retrospective matched cohort study","volume":"17","author":"S Borghs","year":"2017","journal-title":"BMC Neurol"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40258-019-00487-2","article-title":"General Trends in Prices and Prescription Patterns of Anticonvulsants in Germany between 2000 and 2017: Analysis of National and Cohort-Based Data","volume":"17","author":"L M Willems","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study","volume":"75","author":"Z Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.drudis.2009.01.004","article-title":"Insights into liaison between antiepileptic drugs and bone","volume":"14","author":"S Khanna","year":"2009","journal-title":"Drug Discov Today"},{"issue":"07","key":"ref36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1474-4422(03)00435-6","article-title":"Interactions between antiepileptic and chemotherapeutic drugs","volume":"2","author":"C J Vecht","year":"2003","journal-title":"Lancet Neurol"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/157015909788848929","article-title":"Truly \u201crational\u201d polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects","volume":"7","author":"E K St Louis","year":"2009","journal-title":"Curr Neuropharmacol"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14737175.2020.1707668","article-title":"The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection","volume":"20","author":"A Verrotti","year":"2020","journal-title":"Expert Rev Neurother"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1001\/archinte.1989.00390040111022","article-title":"Barbiturate-related connective tissue disorders","volume":"149","author":"R H Mattson","year":"1989","journal-title":"Arch Intern Med"},{"issue":"08","key":"ref40","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"J M Margolis","year":"2014","journal-title":"JAMA Neurol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1590\/S0004-282X2006000200005","article-title":"Pharmacovigilance in epileptic patients using antiepileptic drugs","volume":"64","author":"P A Mei","year":"2006","journal-title":"Arq Neuropsiquiatr"},{"key":"ref42","volume-title":"Effectiveness of antiseizure therapies in the treatment of idiopathic generalised epilepsies, including juvenile myoclonic epilepsy: Epilepsies in children,","author":"National Guideline A. NICE Evidence Reviews Collection","year":"2022"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/epi.16407","article-title":"Doing without valproate in women of childbearing potential with idiopathic generalized epilepsy: Implications on seizure outcome","volume":"61","author":"E Cerulli Irelli","year":"2020","journal-title":"Epilepsia"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2021.05.010","article-title":"Cosmetic adverse effects of antiseizure medications; A systematic review","volume":"91","author":"A A Asadi-Pooya","year":"2021","journal-title":"Seizure"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.yebeh.2012.09.015","article-title":"Monitoring the cognitive effects of antiepileptic pharmacotherapy\u2013approaching the individual patient","volume":"26","author":"J A Witt","year":"2013","journal-title":"Epilepsy Behav"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.yebeh.2019.05.038","article-title":"Comorbidity between epilepsy and cardiac arrhythmias: Implication for treatment","volume":"97","author":"G Zaccara","year":"2019","journal-title":"Epilepsy Behav"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.eplepsyres.2016.03.004","article-title":"Weight gain in children on oxcarbazepine monotherapy","volume":"122","author":"A Garoufi","year":"2016","journal-title":"Epilepsy Res"},{"issue":"09","key":"ref48","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond","volume":"35","author":"W L\u00f6scher","year":"2021","journal-title":"CNS Drugs"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs","volume":"9","author":"M Bialer","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"08","key":"ref50","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.neuron.2023.01.018","article-title":"Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity","volume":"111","author":"E C Rosenberg","year":"2023","journal-title":"Neuron"},{"issue":"09","key":"ref51","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1111\/epi.16674","article-title":"Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs","volume":"61","author":"P N Patsalos","year":"2020","journal-title":"Epilepsia"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"108841","DOI":"10.1016\/j.yebeh.2022.108841","article-title":"Prescription trends in anti-seizure medications for adult patients with epilepsy in Japan: A retrospective cohort study using the database of health insurance claims between 2015 and 2019","volume":"134","author":"K Jin","year":"2022","journal-title":"Epilepsy Behav"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"649589","DOI":"10.3389\/fneur.2021.649589","article-title":"Anti-seizure Medication Prescription in Adult Outpatients With Epilepsy in China, 2013-2018","volume":"12","author":"L Yu","year":"2021","journal-title":"Front Neurol"},{"issue":"06","key":"ref56","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/epi.17226","article-title":"Antiseizure medication treatment pathways for US Medicare beneficiaries with newly treated epilepsy","volume":"63","author":"S W Terman","year":"2022","journal-title":"Epilepsia"},{"issue":"08","key":"ref57","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1212\/WNL.0000000000200779","article-title":"Changes in the Use of Brand Name and Generic Medications and Total Prescription Cost Among Medicare Beneficiaries With Epilepsy","volume":"99","author":"S W Terman","year":"2022","journal-title":"Neurology"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"108666","DOI":"10.1016\/j.yebeh.2022.108666","article-title":"Trends in antiseizure medication prescription patterns among all adults, women, and older adults with epilepsy: A German longitudinal analysis from 2008 to 2020","volume":"130","author":"M Hochbaum","year":"2022","journal-title":"Epilepsy Behav"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1777806.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:43:20Z","timestamp":1730803400000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1777806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":56,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2024,2,7]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["s00431777806"],"URL":"https:\/\/doi.org\/10.1055\/s-0043-1777806","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]}}}